Abstract
Human genetic studies support an inverse causal relationship between leukocyte telomere length (LTL) and coronary artery disease (CAD), but directionally mixed effects for LTL and diverse malignancies. Clonal hematopoiesis of indeterminate potential (CHIP), characterized by expansion of hematopoietic cells bearing leukemogenic mutations, predisposes both hematologic malignancy and CAD. TERT (which encodes telomerase reverse transcriptase) is the most significantly associated germline locus for CHIP in genome-wide association studies. Here, we investigated the relationship between CHIP, LTL, and CAD in Trans-Omics for Precision Medicine (TOPMed) program (N=63,302) and UK Biobank (N=48,658). Bidirectional Mendelian randomization studies were consistent with LTL lengthening increasing propensity to develop CHIP, but CHIP then in turn hastening LTL shortening. We also demonstrated evidence of modest mediation between CHIP and CAD by LTL. Our data promote an understanding of potential causal relationships across CHIP and LTL toward prevention of CAD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The whole-genome sequence for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung, and Blood Institute (NHLBI). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination was provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). Phenotype harmonization for coronary artery disease in TOPMed was supported by National Heart, Lung and Blood Institute (NHLBI) grant number R01HL146860.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All WHI participants provided informed consent and the study was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. All COPDGene participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. All BioMe subjects provided informed consent and the study was approved by the Institutional Review Board of Mount Sinai School of Medicine. All MLOF participants, and for children, their parents, gave written informed consent, which received human subjects Institutional Review Board approval at each hemophilia treatment center local clinical site. All ARIC participants provided written informed consent, and the study was approved by the Institutional Review Boards at the field centers and Collaborative Studies Coordinating Center at the University of North Carolina at Chapel Hill. All CARDIA participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Alabama at Birmingham and the University of Texas Health Science Center at Houston. All CHS participants provided informed consent, and the study was approved by the Institutional Review Board of University Washington. All JHS participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Mississippi Medical Center, Jackson State University, and Tougaloo College. All REDS-III Brazil participants provided written informed consent under a protocol reviewed by institutional review boards at the Vitalant Research Institute and Medical School of the University of Sao Paulo as well as the NHLBI REDS-III Observational Study Monitoring Board. For SARP, informed consent was obtained from the legal guardians of each child and verbal and written consent was obtained from participating children, and the study SARF was approved by the Institutional Review Board of each clinical center. All HCHS/SOL participants provided informed consent, and the study was approved by the Institutional Review Board of local field centers, coordinating centers, and laboratories. All ECLIPSE participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. All THRV participants provided informed consent and the study was approved by the Institutional Review Board of Washington University in St. Louis. All Mayo-VTE participants provided informed consent and the study was approved by the Institutional Review Board of the Mayo Clinic. All Samoan study participants provided written informed consent, and the study was approved by the Institutional Review Board at Brown University, and the Health Research Committee of the Samoa Ministry of Health. All subjects in the Genetics of Asthma in Costa Rica Study (GACR) provided informed consent and the study was approved by the Institutional Review Boards of the Hospital Des Ninos in San Juan Costa Rica and Brigham and Womens Hospital Boston MA. All VU-AF subjects provided informed consent and the study was approved by the Institutional Review Board (IRB) of Vanderbilt University. All FHS participants provided informed consent and the study was approved by the Institutional Review Board of Boston University. All HyperGEN participants provided informed consent, and the study was approved by the Institutional Review Board of the University of Kentucky. All GenSalt participants provided informed consent and the study was approved by the Institutional Review Board of all participating institutes in the US and China. All HVH participants provided written informed consent and study approval was granted by the human subjects committee at Group Health. All GeneSTAR participants provided written informed consent and the study was approved by the Johns Hopkins Medicine Institutional Review Board. All GENOA participants provided informed consent and the study protocol was approved by the Human Studies Review Boards of the University of Mississippi, the Mayo Clinic, and the University of Texas. All subjects in the CFS provided informed consent and the study was approved by the Institutional Review Board of Case Western Reserve University and Mass General Brigham (formerly Partners HealthCare). All BAGS participants gave verbal and written consent as approved by the Johns Hopkins Institutional Review Board and the Barbados Ministry of Health. All Amish participant provided informed consent and the study protocols were approved by the institutional review board at the University of Maryland Baltimore. All GOLDN participants provided informed consent, and the study was approved by the Institutional Review Board of the University of Kentucky. All DHS participants provided written informed consent, and study protocols were approved by the institutional review board at Wake Forest School of Medicine. All SAFS participants provided informed consent, and the study was approved by Institutional Review Board at the University of Texas Rio Grande Valley. All PharmHU participants provided written informed consent and the study was approved by the Baylor College of Medicine IRB. All Boston Early-Onset COPD Study participants provided written informed consent, and the study was approved by the Institutional Review Board at Brigham and Womens Hospital. All VAFAR participants provided informed consent and the study was approved by the Institutional Review Board of Vanderbilt University. All participants in the UK Biobank study provided written informed consent and the ethics approval for the UK Biobank study was obtained as described before. UK Biobank Resource was used under application number 7089. Secondary use of the UK Biobank data was approved by the Massachusetts General Hospital institutional review board (protocol 2013P001840).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from TOPMed are available via dbGaP. Data from UK Biobank will be made available through an application.
